-The Biocon India group promoter of Biocon India Ltd. Ms Kiran Mazumdar Shaw, Chairman and Managing Director of Biocon India Group.
-Biocon India appointed DSP Merrill Lynch and Kotak Mahindra for its Rs 150-crore IPO scheduled for June next year. Biocon-Shantha Biotech, the 50:50 joint venture between Biocon India and Shantha Biotechnics, focuses on the domestic and global human insulin markets by maximizing on R&D manufacturing and regulatory capacities of the two companies.
-ICICI Venture offloads 10-pc stake in Biocon
-Clinigene International inaugurates human pharmacology unit for clinical trials
-Comes out with an Initial Public Offering (IPO) of 10 million shares at a price of Rs 315 per share for a face value of Rs 5 per share which constitutes 10% of the post-issue capital (Rs 100 crore), listed at Rs 425
-Biocon Ltd has entered into a nine-year export contract with US major Bristol-Myers Squibb Co to supply the bulk form of its recombinant human insulin
-Biocon forays into lifestyle drugs market
-Biocon's clinical research arm, Clinigene International Pvt Ltd. re-accredited by the College of American Pathologists (CAP) following a recent inspection
-Biocon Ltd has informed that in an unusual commercial transaction between Cuba and USA, a Californian Biotechnology Company, CancerVax Corporation received a rare US Government approval to License three experimental cancer drugs from a leading Cuban Institute (CIMAB)
-Biocon said on July 26 that its Cuban partner CIMAB (Centre for Molecular Immunology) in the joint venture with Biocon Biopharmaceuticals will be able to license out three experimental cancer drugs to a Californian Biotechnology company, CancerVax Corporation
-Biocon, Syngene enters into Research Agreement with Novartis Institutes for Biomedical Research Inc
-Biocon unveils new bio insulin
Biocon signs MoU with Karolinska Institute.
-Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, has been honoured with the Corporate Leadership Award 2005 of the American India Foundation (AIF)
-Biocon signs Licensing agreement with Bentley Pharmaceuticals Inc.
-Biocon ties up with ICICI Prudential Life Insurance
-Biocon concludes Phase-IV trials of Insugem
-Biocon Ltd and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU to establish a JV to manufacture and market a range of Bio-pharmaceuticals for the GCC countries (Gulf Cooperation Council).
-Biocon Ltd on March 14, 2007 has announced that its subsidiary Company Syngene has entered into a research partnership with Bristol-Myers Squibb.
-Biocon signs MOU with Neopharma for a JV
-The Company has issued Bonus Shares in the Ratio of 1:1.
- Biocon and Amylin Pharmaceuitcals Inc have entered into an exclusive agreement to jointly develop, commercialise and manufacture a new peptide therapeutic for potential treatment of diabetes. The two companies will share development costs.
-Biocon launches BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics
-Biocon joins hands with Amylin Pharmaceuticals
-Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management
- Biocon has launched its new 'comprehensive care' division, dedicated to provide affordable solutions to critical illnesses such as nosocomial infections, post surgical complications, trauma and medical emergencies.
- Biocon has signed an agreement with Teleradiology Solutions to provide teleradiology reporting services to Clinigene, Biocon's clinical research arm.